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Objectives: Data on consumption of tetracyclines, sulphonamides and trimethoprim, and other antibacterials
were collected from 30 EU/European Economic Area (EEA) countries over two decades. This article reviews tem-
poral trends, seasonal variation, presence of change-points and changes in the composition of main subgroups
of tetracyclines, sulphonamides and trimethoprim and other antibacterials.
Methods: For the period 1997–2017, data on consumption of tetracyclines (ATC group J01A), sulphonamides
and trimethoprim (ATC group J01E), and other antibacterials (ATC group J01X) in the community and aggregated
at the level of the active substance, were collected using the WHO ATC/DDD methodology (ATC/DDD index
2019). Consumption was expressed in DDD per 1000 inhabitants per day and in packages per 1000 inhabitants
per day. Consumption of tetracyclines, sulphonamides and trimethoprim, and other antibacterials was analysed
based on ATC-4 subgroups and presented as trends, seasonal variation, presence of change-points and compos-
itional changes.
Results: In 2017, consumption of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in
the community expressed in DDD per 1000 inhabitants per day varied considerably between countries. Between
1997 and 2017, consumption of tetracyclines did not change significantly, while its seasonal variation signifi-
cantly decreased over time. Consumption of sulphonamides and trimethoprim significantly decreased until
2006, and its seasonal variation significantly decreased over time. The consumption of other antibacterials
showed no significant change over time or in seasonal variation.
Conclusions: Consumption and composition of tetracyclines, sulphonamides and trimethoprim, and other anti-
bacterials showed wide variations between EU/EEA countries and over time. This represents an opportunity to
further reduce consumption of these groups in some countries and improve the quality of their prescription.
Introduction
This article presents data from the European Surveillance of
Antimicrobial Consumption Network (ESAC-Net,1 formerly ESAC)
on consumption of tetracyclines, sulphonamides and trimetho-
prim, and other antibacterials in the community (i.e. primary care
sector) for 30 EU/European Economic Area (EEA) countries in 2017
(Table 1). It updates a previous ESAC study published in 2011, and
in doing so it provides updated comparable and reliable information
on antibiotic consumption that can aid in fighting the global problem
of antimicrobial resistance.2 In 2017, tetracyclines, sulphonamides
VC The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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Table 1. Classification of tetracyclines (J01A), sulphonamides and trimethoprim (J01E), and other antibacterials (J01X; ATC/DDD index 2019)
Tetracyclines
J01AA01 Demeclocycline J01AA08 Minocyclinea
J01AA02 Doxycyclinea J01AA09 Rolitetracyclineb
J01AA03 Chlortetracyclineb J01AA10 Penimepicyclineb
J01AA04 Lymecyclinea J01AA11 Clomocyclineb
J01AA05 Metacycline J01AA12 Tigecycline
J01AA06 Oxytetracycline J01AA20 Combinations of tetracyclinesb
J01AA07 Tetracycline J01AA56 Oxytetracycline, combinations
Sulphonamides and trimethoprim
Trimethoprim and derivatives Long-acting sulphonamides
J01EA01 Trimethoprima J01ED01 Sulfadimethoxineb
J01EA02 Brodimoprimb J01ED02 Sulfaleneb
J01EA03 Iclaprimb J01ED03 Sulfametomidineb
J01ED04 Sulfametoxydiazineb
Short-acting sulphonamides J01ED05 Sulfamethoxypyridazine
J01EB01 Sulfaisodimidineb J01ED06 Sulfaperinb
J01EB02 Sulfamethizole J01ED07 Sulfamerazineb
J01EB03 Sulfadimidine b J01ED08 Sulfaphenazoleb
J01EB04 Sulfapyridine J01ED09 Sulfamazonb
J01EB05 Sulfafurazoleb J01ED20 Combinationsb
J01EB06 Sulfanilamideb
J01EB07 Sulfathiazoleb Combinations of sulphonamides and trimethoprim, including derivatives
J01EB08 Sulfathioureab J01EE01 Sulfamethoxazole and trimethoprima
J01EB20 Combinationsb J01EE02 Sulfadiazine and trimethoprimb
J01EE03 Sulfametrole and trimethoprim
Intermediate-acting sulphonamides J01EE04 Sulfamoxole and trimethoprimb
J01EC01 Sulfamethoxazoleb J01EE05 Sulfadimidine and trimethoprimb
J01EC02 Sulfadiazine J01EE06 Sulfadiazine and tetroxoprimb
J01EC03 Sulfamoxoleb J01EE07 Sulfamerazine and trimethoprimb
J01EC20 Combinationsb
Other antibacterials
Glycopeptide antibacterials Nitrofuran derivatives
J01XA01 Vancomycin J01XE01 Nitrofurantoina
J01XA02 Teicoplanin J01XE02 Nifurtoinola
J01XA03 Televancinb J01XE03 Furazidinc




J01XB01 Colistin J01XX02 Xibornolb
J01XB02 Polymyxin Bb J01XX03 Clofoctol
J01XX04 Spectinomycin
Steroid antibacterials J01XX05 Methenaminea
J01XC01 Fusidic acid J01XX06 Mandelic acid
J01XX07 Nitroxoline
Imidazole derivatives J01XX08 Linezolid
J01XD01 Metronidazolea J01XX09 Daptomycin
J01XD02 Tinidazole J01XX10 Bacitracinb
J01XD03 Ornidazole J01XX11 Tedizolidc
Bold type indicates that consumption was part of the top 90% of the community consumption of tetracyclines (J01A), sulphonamides and trimetho-
prim (J01E), or other antibacterials (J01X) in 28 EU/EEA countries in 2017; Italic type indicated that no consumption of this antibiotic was reported in
28 EU/EEA countries in 2017.
aConsumption was part of the top 90% of the community consumption of tetracyclines (J01A), sulphonamides and trimethoprim (J01E), or other
antibacterials (J01X) in 30 EU/EEA countries in 2009.
bNo consumption of this antibiotic was reported in 30 EU/EEA countries in 2009.
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and trimethoprim, and other antibacterials represented 11.3%,
2.9% and 6.1% of total antibiotic consumption in the community,
respectively.3 The objective of this study was to analyse temporal
trends, seasonal variation and the presence of change-points in
consumption of tetracyclines, sulphonamides and trimethoprim,
and other antibacterials for the period 1997–2017 in the commu-
nity as well as to analyse their composition over time.
Methods
The methods for collecting and analysing the data are described in the
introductory article of this series.4 In summary, data on consumption of tet-
racyclines, i.e. Anatomical Therapeutic Chemical (ATC) group J01A, sulpho-
namides and trimethoprim (ATC group J01E), and other antibacterials (ATC
group J01X) in the community and aggregated at the level of the active
substance, were collected using the WHO ATC/DDD methodology (ATC/DDD
index 20195) and expressed in DDD per 1000 inhabitants per day. In add-
ition, where data were available, consumption was also expressed in
packages per 1000 inhabitants per day. There are 14, 33 and 26 unique ATC
codes for tetracyclines, sulphonamides and trimethoprim, and other
antibacterials, respectively, in the ATC/DDD index 2019. Compared with
previous descriptions of the consumption of other antibacterials in the
community, two additional nitrofuran derivatives, i.e. furazidin (J01XE03)
and nitrofurantoin, combinations (J01XE51), and one additional other
antibacterial substance, i.e. tedizolid (J01XX11), have been assigned an ATC
code by the WHO (Table 1).2
The evolution of the number of DDD per package over time was
assessed using a linear mixed model. The temporal trend, seasonal vari-
ation and presence of change-points for tetracyclines, sulphonamides and
trimethoprim and other antibacterials were assessed using a non-linear
change-point mixed model fitted to quarterly data expressed in DDD per
1000 inhabitants per day from 1997 to 2017.6 The relative proportions of
the main subgroups for sulphonamides and trimethoprim, and other anti-
bacterials were assessed through a compositional data analysis modelling




An overview of consumption of tetracyclines (ATC J01A) in the
community, expressed in DDD and packages per 1000 inhabitants
per day for all participating countries between 1997 and 2017 is
available as Supplementary data at JAC Online (Tables S1 and S2,
respectively).
Consumption of tetracyclines in the community in 2017
In 2017, two substances accounted for 90% of consumption of
tetracyclines in the community expressed in DDD per 1000 inhabi-
tants per day: doxycycline (75.8% in 2017 compared with 74.9% in
2009) and lymecycline (14.8% in 2017 compared with 10.2% in
2009) (Table 1).
Figure 1 shows the consumption of tetracyclines in the commu-
nity expressed in DDD per 1000 inhabitants per day in 2017, which
varied by factor 16 between countries with the highest (5.0 DDD per
1000 inhabitants per day in Iceland) and the lowest (0.3 DDD per
1000 inhabitants per day in Slovenia) consumption. This was higher
than in 2009 (factor of 10, from 5.1 DDD per 1000 inhabitants per
day in Iceland to 0.5 DDD per 1000 inhabitants per day in Italy).
Doxycycline was the only tetracycline prescribed in Croatia,


























































































































































Figure 1. Consumption of tetracyclines (ATC J01A) in the community, expressed in DDD (ATC/DDD index 2019) per 1000 inhabitants per day, 30 EU/
EEA countries, 2017. For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania, total care data, i.e. community and
hospital sector combined, are used.
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of tetracyclines in the community in all but four countries
(Belgium, Denmark, Sweden and the United Kingdom, where its
consumption represented >30%). Lymecycline was the most
consumed in Sweden (51.5% of consumption of tetracyclines in
the community), and represented >30% in Belgium, Norway and
the United Kingdom, and >20% in Austria, Denmark, Ireland
and Finland. Minocycline represented >20% of consumption of tet-
racyclines in the community in Belgium, Luxembourg and Malta.
The substance tetracycline (J01AA07) was the most consumed in
Denmark (34.6%) and represented >10% in Finland, Norway and
Romania (total care data, i.e. community and hospital sector com-
bined). Tigecycline for parenteral use was consumed in the
community in six countries ranging from 0.006 DDD per 1000
inhabitants per day in Greece to 0.001 DDD per 1000 inhabitants
per day in Malta.
Figure 2 shows consumption of tetracyclines in the community
expressed in packages per 1000 inhabitants per day for 20
EU/EEA countries in 2017. Bulgaria ranked 11th for its consump-
tion of tetracyclines in DDD per 1000 inhabitants per day and
5th in packages per 1000 inhabitants per day, Lithuania 14th
and 8th, France 3rd and 9th, Sweden 6th and 12th, and
Denmark 13th and 18th, respectively (Table 2). Consequently,
the lowest mean number of DDD per package was found in
Bulgaria (9 DDD per package) and Lithuania (10.2 DDD per pack-
age), the highest in France (22.6 DDD per package), Sweden
(23.5 DDD per package) and Denmark (27.5 DDD per package).
The number of DDD per package ranged from 7.9 in Greece
to 27.5 in Denmark and was higher than in 2009 (from 6.3 in
Bulgaria to 22.8 in Denmark). In the EU/EEA countries, the num-
ber of DDD per package did not change significantly over time
during 1997–2017.
Longitudinal data analysis, 1997–2017
The best fit was obtained for a model including three change-
points: one in the first quarter of 2004, another in the third quarter
of 2009 and a third one in the first quarter of 2014. The final model
fits the observed data well (Figure S1). The longitudinal data
analysis estimated an average consumption of tetracyclines of
2.875 (SE 0.356) DDD per 1000 inhabitants per day in the first quar-
ter of 1997, which did not change significantly over time: #0.009
(SE 0.008) DDD per 1000 inhabitants per day per quarter until the
first quarter of 2004, then #0.001 (SE 0.011) DDD per 1000 inhabi-
tants per day per quarter until the third quarter of 2009, then
!0.011 (SE 0.016) DDD per 1000 inhabitants per day per quarter
until the first quarter or 2014, and finally #0.007 (SE 0.020) DDD
per 1000 inhabitants per day per quarter. A statistically significant
seasonal variation was observed with an amplitude of 0.598
(SE 0.056) DDD per 1000 inhabitants per day, which decreased sig-
nificantly over time by 0.005 (SE 0.001) DDD per 1000 inhabitants
per day per quarter (Figure 3).
Based on the fitted model, consumption of tetracyclines in the
community in 1997 was significantly higher than average in
Belgium, Finland, Iceland, Latvia and Poland, and significantly
lower than average in Austria, Croatia, Denmark, Italy, Portugal,
Slovakia, Slovenia and Spain (observed profiles shown in Figure S2
and S3). The seasonal variation was significantly larger than aver-
age in Belgium, Finland, Iceland, the Netherlands, Poland and
Sweden, and significantly smaller than average in Denmark,
Greece, Ireland, Italy, Portugal, Slovenia, Spain and the United
Kingdom. The decrease in consumption of tetracyclines in the
community between 1997 and the first quarter of 2004 was sig-
nificantly higher than average in Belgium, Finland, Hungary and












































































































Figure 2. Consumption of tetracyclines (ATC J01A) in the community, expressed in packages per 1000 inhabitants per day, 20 EU/EEA countries in
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the second quarter of 2004 and the third quarter of 2009 was
significantly larger than average in Czechia, Ireland, Latvia and
Slovakia. The increase in consumption of tetracyclines between
the fourth quarter of 2009 and the first quarter of 2014 was signifi-
cantly larger than average in the United Kingdom. The decrease
in consumption of tetracyclines between the second quarter of
2014 and 2017 was significantly higher than average in Finland.
Between 2009 and 2017, consumption of tetracyclines
increased in 12 countries (Table S1). The largest increases were
observed for Greece, Spain (including private prescriptions from
2016 onwards) and the United Kingdom, while the largest
decreases were observed for Estonia, Germany and Luxembourg.
The increase in consumption of tetracyclines was mainly the result
of the increase in doxycycline consumption. For Malta, a substan-
tial increase in lymecycline consumption was also observed. As
in 2009, Italy had the lowest consumption of tetracyclines in 2017.
Compositional data analysis (1997–2017)
For the tetracyclines, grouping into subgroups is not available from
the ATC classification5 and variation in the consumption among
the different tetracycline substances was not assessed.
Sulphonamides and trimethoprim
An overview of consumption of sulphonamides and trimethoprim
(ATC J01E) in the community, expressed in DDD and packages per
1000 inhabitants per day for all participating countries between
1997 and 2017 is available as Supplementary data (Tables S3 and
S4, respectively).
Consumption of sulphonamides and trimethoprim in 2017
In 2017, the two most used substances accounted for 90% of
the consumption of sulphonamides and trimethoprim in the
community expressed in DDD per 1000 inhabitants per day: sulfa-
methoxazole and trimethoprim (65.8% in 2017 compared with
67.7% in 2009) and trimethoprim (29.4% in 2017 compared with
29.8% in 2009) (Table 1).
Figure 4 shows the consumption of sulphonamides and
trimethoprim in the community expressed in DDD per 1000 inhabi-
tants per day in 2017. Consumption of sulphonamides and
trimethoprim varied by a factor of 105 between countries with
the highest (1.04 DDD per 1000 inhabitants per day in the United
Kingdom) and the lowest (0.01 DDD per 1000 inhabitants per day
in Lithuania) consumption (Table S3), which was lower than in
2009 (factor of 203, from 1.18 DDD per 1000 inhabitants per day in
the United Kingdom to 0.006 DDD per 1000 inhabitants per day
in Lithuania).
For six countries (Belgium, Bulgaria, Croatia, Hungary, Italy and
Luxembourg), consumption of sulphonamides and trimethoprim
in the community was represented by a single substance, namely
sulfamethoxazole plus trimethoprim (J01EE01). In another eight
countries, combinations of sulphonamides and trimethoprim,
including derivatives (J01EE) represented >90% of the consump-
tion of sulphonamides and trimethoprim in the community, and it
represented >80% of this consumption in Germany and Poland.
In Ireland and Lithuania, consumption of sulphonamides and
trimethoprim in the community was only represented by trime-
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consumption of sulphonamides and trimethoprim in the commu-
nity in Iceland, >80% in the United Kingdom, >70% in Denmark
and Finland and >50% in Austria. Denmark was the only country
consuming a substantial proportion of short-acting sulphona-
mides (>20%, sulfamethizole). The highest consumption of inter-
mediate-acting sulphonamides (sulfadiazine) was found in Malta
(>30%), followed by Iceland and France (>5%), and Cyprus (total
care data) and Germany (>1%). Consumption of sulfadiazine was
<1% in six countries and no consumption of this substance was
reported for 14 countries. In 2017, no country consumed long-act-
ing sulphonamides in the community.
Figure 5 shows the consumption of sulphonamides and tri-
methoprim in the community expressed in packages per 1000
inhabitants per day for 20 EU/EEA countries in 2017. In addition,
country ranking is depicted according to both DDD and packages
per 1000 inhabitants per day in 2017 (Table 3). The number of DDD
per package ranged from 0.2 in Lithuania to 22.9 in Slovakia (2016
data). A high number of DDD per package was associated with a
higher ranking of consumption expressed in DDD per 1000 inhabi-
tants per day than in packages per 1000 inhabitants per day.
Slovakia (2016 data) and Ireland, for example, had a higher rank-
ing in DDD than in packages per 1000 inhabitants per day because
of the high number of DDD per package. Conversely, Iceland and
Lithuania, for example, had a lower ranking in DDD than in pack-
ages per 1000 inhabitants per day because of low number of DDD
per package. In the EU/EEA countries, the number of DDD per pack-
age did not change significantly over time during 1997–2017.
Longitudinal data analysis, 1997–2017
The best fit was obtained for a model including two change-points:
one in the third quarter of 2006 and another in the second quarter
of 2009. The final model fits the observed data well (Figure S4).
The longitudinal data analysis estimated an average consumption
of sulphonamides and trimethoprim in the EU/EEA of 1.767
(SE 0.283) DDD per 1000 inhabitants per day in the first quarter of
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Figure 3. Estimated trend (solid line) and linear trend (dashed line) of consumption of tetracyclines (ATC J01A) in the community based on quarterly
data, 25 EU/EEA countries, 1997–2017. b0, predicted consumption in the first quarter of 1997; b1, predicted increase (if positive)/decrease (if negative)
in consumption per quarter; b2, predicted difference in slope after versus before the first change-point; b3, predicted difference in slope after versus
before the second change-point; b4, predicted difference in slope after versus before the third change-point; b0
S, predicted amplitude of the upward
winter and downward summer peak in consumption; b1
S, predicted increase (if positive)/decrease (if negative) of the amplitude of the upward winter
and downward summer peak in consumption per quarter; d, shift in timing of the upward winter and downward summer peak from one year to an-
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Figure 4. Consumption of sulphonamides and trimethoprim (ATC J01E) in the community, expressed in DDD (ATC/DDD index 2019) per 1000 inhabi-
tants per day, 30 EU/EEA countries, 2017. For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania, total care data,
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Figure 5. Consumption of sulphonamides and trimethoprim (ATC J01E) in the community, expressed in packages per 1000 inhabitants per day, 20
EU/EEA countries, 2017. For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania, total care data, i.e. community
and hospital sector combined, are used.








ent_2/ii45/6328685 by 81728827 user on 20 O
ctober 2021
1997, which significantly decreased by #0.018 (SE 0.009) DDD per
1000 inhabitant per day per quarter until the third quarter of 2006.
After the first change-point, consumption of sulphonamides and
trimethoprim did not change significantly; !0.013 (SE 0.015) DDD
per 1000 inhabitants per day per quarter up to the second quarter
of 2009, then !0.010 (SE 0.016) DDD per 1000 inhabitants per day
per quarter. A statistically significant seasonal variation was
observed with an amplitude of 0.147 (SE 0.028) DDD per 1000
inhabitants per day, which decreased significantly over time by
0.001 (SE 0.0002) DDD per 1000 inhabitants per day per quarter
(Figure 6).
Based on the fitted model, consumption of sulphonamides and
trimethoprim in the community in 1997 was significantly larger
than average in Iceland, Latvia and Poland, and significantly
smaller than average in Austria, Belgium, Denmark, Germany,
Ireland, Italy, Luxembourg, the Netherlands, Portugal, Slovenia,
Spain, Sweden and the United Kingdom (observed profiles shown
in Figures S5 and S6). The seasonal variation was significantly
larger than average in Czechia, Hungary, Latvia and Poland, and
significantly smaller than average in Austria, Denmark, the
Netherlands, Portugal, Spain, Sweden and the United Kingdom.
The decrease in consumption of sulphonamides and trimethoprim
in the community between 1997 and the third quarter of 2006
was significantly larger than average in Latvia and Poland. The in-
crease in consumption of sulphonamides and trimethoprim be-
tween the last quarter of 2006 and the second quarter of 2009
was significantly larger than average in Latvia.
Compositional data analysis, 1997–2017
Although consumption of sulphonamides and trimethoprim in the
community significantly decreased over time until 2006 and later
remained stable, the proportional consumption of trimethoprim
and derivatives (J01EA) significantly increased relative to that of all
other subgroups of sulphonamides and trimethoprim. The propor-
tional consumption of long-acting sulphonamides (J01ED) signifi-
cantly decreased relative to that of all other subgroups of
sulphonamides and trimethoprim. In addition, the proportional
consumption of short-acting sulphonamides (J01EB) significantly
decreased relative to that of intermediate-acting sulphonamides
(J01EC) and of sulphonamides and trimethoprim, including deriva-
tives (J01EE) (Table 4).
Trends of proportional consumption in individual countries are
shown in Figure S7. When comparing the composition of the con-
sumption of sulphonamides and trimethoprim in 2017 with that in
2009, we focused on countries reporting consumption in both
years (i.e. all countries except Belgium and Slovenia). For the pro-
portion of trimethoprim and derivatives (J01EA), both increases
and decreases were observed. The largest increases were
observed for Iceland (!40.32%), Ireland (!26.40%) and Poland
(!15.82%), while the largest decreases were observed for Finland
(#28.57%), Norway (#20.52%) and Sweden (#15.39%). These
changes were counteracted by decreases (or increases, respective-
ly) in the proportion of combinations of sulphonamides and tri-
methoprim (J01EE). The proportion of short-acting sulphonamides
only changed only for Denmark (#14.50%). The proportion of
intermediate-acting sulphonamides remained stable for most
countries, but changes >5% were observed for Malta (!28.01%)
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consumed in the community in any of the countries in 2017, while
in 2009 they were still consumed in the United Kingdom (0.04%).
Other antibacterials
An overview of consumption of other antibacterials (ATC J01X) in
the community, expressed in DDD and packages per 1000 inhabi-
tants per day for all participating countries between 1997 and 2017
is available as Supplementary data (Tables S5 and S6, respectively).
Consumption of other antibacterials in the community in
2017
In 2017, the three most used substances accounted for 90% of the
consumption of other antibacterials in the community expressed
in DDD per 1000 inhabitants per day: nitrofurantoin (58.5% in 2017
compared with 55.3% in 2009), methenamine hippurate/mande-
late (22.6% in 2017 compared with 23.3% in 2009) and fosfomycin
(10.6% in 2017 compared with 4.7% in 2009) (Table 1).
Figure 7 shows the consumption of other antibacterials (J01X)
in the community expressed in DDD per 1000 inhabitants per day
in 2017. Consumption of other antibacterials varied by a factor of
130 between countries with the highest (4.32 DDD per 1000 inhab-
itants per day in Poland) and the lowest [0.03 DDD per 1000 inhabi-
tants per day in Ireland; consumption of nitrofurantoin (J01XE01)
not included] consumption (Table S5). This was much lower than
in 2009 (factor of 892, from 2.85 DDD per 1000 inhabitants per day
in Norway to 0.003 DDD per 1000 inhabitants per day in Bulgaria).
Nitrofuran derivatives (J01XE) represented >50% of the con-
sumption of other antibacterials in the community in 17 countries:
>90% in Belgium, Croatia, Czechia (2015 data), Estonia, Latvia,
3























1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Time (1997-2017)




















b0 b1 b2 b3 b4 bS0 b
S
1 d
Figure 6. Estimated trend (solid line) and linear trend (dashed line) of consumption of sulphonamides and trimethoprim (ATC J01E) in the commu-
nity expressed based on quarterly data, 25 EU/EEA countries, 1997–2017. b0, predicted consumption in the first quarter of 1997; b1, predicted
increase (if positive)/decrease (if negative) in consumption per quarter; b2, predicted difference in slope after versus before the first change-point; b3,
predicted difference in slope after versus before the second change-point; b4, predicted difference in slope after versus before the third change-point;
b0
S, predicted amplitude of the upward winter and downward summer peak in consumption; b1
S, predicted increase (if positive)/decrease (if negative)
of the amplitude of the upward winter and downward summer peak in consumption per quarter; d, shift in timing of the upward winter and down-
ward summer peak from one year to another. An asterisk indicates that the result was statistically significant at significance level 0.05.
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Lithuania, Malta, the Netherlands, Poland and Slovenia; >80% in
Portugal and the United Kingdom; >70% in Austria, Germany and
Greece and >50% in Cyprus (total care data, community and
hospital sector combined) and Iceland. In Spain and Norway, nitro-
furan derivatives represented <20% of the consumption of other
antibacterials. No consumption of this subgroup was reported
for Bulgaria, Hungary and Slovakia (2016 data). In all but two
countries, nitrofurantoin was the only nitrofuran derivative con-
sumed [nifurtoinol in Belgium (24.4%) and Luxembourg (6.0%)].
The subgroup ‘other antibacterials’ (J01XX) represented >70%
of the other antibacterials (J01X) in eight countries (Bulgaria,
Finland, Hungary, Italy, Luxembourg, Norway, Spain and Sweden),
and it represented >20% in Denmark, France, Germany, Iceland,
Ireland [consumption of nitrofurantoin (J01XE01) not included]
and Slovakia (2016 data). Methenamine hippurate/mandelate
and fosfomycin, and to a lesser extent nitroxoline and linezolid,
were also consumed, each country using a substantial proportion
of only one of these substances. The highest consumption of gly-
copeptide antibacterials (J01XA, i.e. parenteral vancomycin and
teicoplanin) was reported for Cyprus (total care data, i.e. commu-
nity and hospital sector combined) followed by Greece, Romania
(total care data), Czechia (2015 data) and the United Kingdom.
For six countries, no consumption of glycopeptide antibacterials
was reported in the community. The highest consumption of
polymyxins (J01XB; only represented by parenteral colistin) in the
community was observed for the United Kingdom, followed by the
Netherlands, Greece and Denmark. Steroid antibacterials (J01XC;
represented by fusidic acid) were consumed by 14 countries and
represented 10.5% of the consumption of other antibacterials
(J01X) in Ireland [consumption of nitrofurantoin (J01XE01) not
included] and France. Imidazole derivatives [J01XD, represented
mainly by parenteral metronidazole; and not including oral metro-
nidazole (P01AB01)] were consumed in the community in 22 coun-
tries with the highest consumption reported in Cyprus (total
care data, i.e. community and hospital sector combined), followed
by Greece, Romania (total care data) and Czechia (2015 data).
Table 4. Change in the composition of the consumption of sulphona-
mides and trimethoprim (ATC J01E) in the community, expressed in
DDD (ATC/DDD index 2019) per 1000 inhabitants per day, 30 EU/EEA
countries, as a function of time during 1997–2017
J01EA J01EB J01EC J01ED J01EE
J01EA 0.1194 0.0212 0.4550 0.0203
J01EB #0.1194 #0.0983 0.3355 #0.0992
J01EC #0.0212 0.0983 0.4338 #0.0009
J01ED #0.4550 #0.3355 #0.4338 #0.4347
J01EE #0.0203 0.0992 0.0009 0.4347
Values are estimated changes in the log ratio of the row versus column
subgroup of antibiotics with increasing time. Bold type indicates a
statistically significant effect; positive values represent an increase and
negative values represent a decrease.
J01EA, trimethoprim and derivatives; J01EB, short-acting sulphona-
mides; J01EC, intermediate-acting sulphonamides; J01ED, long-acting
































































































































































Figure 7. Consumption of other antibacterials (ATC J01X) in the community, expressed in DDD (ATC/DDD index 2019) per 1000 inhabitants per day,
30 EU/EEA countries in 2017. For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania, total care data, i.e. commu-
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Figure 8 shows consumption of other antibacterials in the com-
munity expressed in packages per 1000 inhabitants per day for 20
EU/EEA countries in 2017. The number of DDD per package ranged
from 1.6 in Slovakia (2016 data) to 22.5 in Denmark. A high number
of DDD per package was generally associated with a higher ranking
in DDD per 1000 inhabitants per day than in packages per 1000
inhabitants per day (Table 5). Denmark and Finland had a higher
ranking in DDD than in packages per 1000 inhabitants per day be-
cause of the high number of DDD per package. Inversely, Greece,
France and Italy, for example, had a lower ranking in DDD than in
packages per 1000 inhabitants per day because of the low number
of DDD per package. In the EU/EEA countries, the number of DDD
per package significantly increased over time during 1997–2017,
with the steepness of this increase significantly reducing over the
years.
Longitudinal data analysis, 1997–2017
The best fit was obtained for a model including three change-
points: one in the second quarter of 2006, another in the second
quarter of 2011 and a third one in the first quarter of 2015. The
final model fits the observed data well (Figure S8). The longitudinal
data analysis estimated an average consumption of other antibac-
terials in the EU/EEA of 0.723 (SE 0.207) DDD per 1000 inhabitants
per day in the first quarter of 1997 which did not change signifi-
cantly over time: #0.001 (SE 0.005) DDD per 1000 inhabitants per
day per quarter up to the second quarter of 2006, then !0.016 (SE
0.010) DDD per 1000 inhabitants per day per quarter up to the se-
cond quarter of 2011, then!0.010 (SE 0.013) DDD per 1000 inhab-
itants per day per quarter up to the first quarter of 2015, and finally
#0.011 (SE 0.007) DDD per 1000 inhabitants per day per quarter.
Furthermore, the longitudinal data analysis showed no significant
seasonal variation for the consumption of other antibacterials
(Figure 9).
Based on the fitted model, consumption of other antibacterials
in the community in 1997 was significantly higher than average in
Belgium, Estonia, Finland, Latvia, Luxembourg and Sweden, and
lower than average in Austria, Croatia, Germany, Hungary, Poland,
Slovakia, Slovenia, Spain and the United Kingdom (observed pro-
files shown in Figures S9 and S10). The seasonal variation was sig-
nificantly larger than average in Czechia. The decrease in
consumption of other antibacterials in the community between
1997 and the second quarter of 2006 was significantly larger than
average in Czechia, Estonia, Iceland, Latvia and Luxembourg. The
increase between the third quarter of 2006 and the second quarter
of 2011 was significantly larger than average in Iceland, Lithuania
and Portugal. The increase between the third quarter of 2011 and
the first quarter of 2015 was significantly larger than average in
Lithuania. The decrease between the second quarter of 2015 and
the last quarter of 2017 was significantly larger than average in
Czechia.
Compositional data analysis, 1997–2009
The proportional consumption of polymyxins (J01XB) significantly
increased over time relative to that of the other subgroups (Table
3). The proportional consumption of steroid antibacterials (J01XC)
significantly decreased relative to that of the other subgroups ex-
cept imidazole derivatives (J01XD; no significant change). The rela-
tive consumption of glycopeptide antibacterials (J01XA)
significantly decreased relative to that of other antibacterials



















































































































Figure 8. Consumption of other antibacterials (ATC J01X) in the community, expressed in packages per 1000 inhabitants per day 20 EU/EEA coun-
tries, 2017. For Czechia, 2015 data are used. For Slovakia, 2016 data are used. For Cyprus and Romania, total care data, i.e. community and hospital
sector combined, are used. For Ireland, nitrofurantoin (J01XE01) consumption is not included.
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(J01XD) significantly decreased relative to that of nitrofuran deriv-
atives (J01XE) (Table 6).
Trends of proportional consumption for individual countries are
shown in Figure S11. When comparing the composition of the con-
sumption of other antibacterials in 2017 with that in 2009, the pro-
portion of polymyxins increased for most of the participating
countries. Increases >5% were reported for Ireland [!14.44%;
consumption of nitrofurantoin (J01XE01) not included], Slovakia
(!11.61%; 2016 data) and Bulgaria (!5.54%). The proportional
consumption of steroid antibacterials decreased for most of the
countries, with decreases >5% reported for Iceland (#40.96%),
Ireland [#20.20%; consumption of nitrofurantoin (J01XE01) not
included], Austria (#10.13%), Greece (#7.83%), and France
(#7.73%). The proportional consumption of nitrofuran derivatives
decreased for most countries, with the largest decreases reported
for Hungary (#71.06%), Luxembourg (#68.03%) and Denmark
(#46.71%). The proportional consumption of the ‘other antibacte-
rials’ subgroup (J01XX) increased in most countries, with the larg-
est increases reported for Bulgaria (!77.74%), Luxembourg
(!68.27%), Hungary (!66.93%) and Denmark (!49.12%). Overall,
the increase was mainly attributable to an increased consumption
of fosfomycin (J01XX01). The proportions of glycopeptide antibac-
terials and imidazole derivatives showed both increases and
decreases. The largest increases in the consumption of glycopep-
tide antibacterials in the community were observed for Romania
(!14.70%; total care data, i.e. community and hospital sector
combined; coverage in 2009 limited to 30%–40%), Ireland
[!6.28%; consumption of nitrofurantoin (J01XE01) not included]
and Cyprus (!1.90%; total care data), and the largest decreases
for Bulgaria (#5.72%), Slovakia (#0.87%; 2016 data) and Greece
(#0.67%). The largest increases in the consumption of imidazole
derivatives in the community were observed for Slovakia
(!22.46%), Cyprus (!6.53%; total care data) and Greece
(!2.60%), and the largest decreases for Bulgaria (#77.56%),
Romania (#73.75%; total care data; coverage in 2009 limited to
30%–40%) and Lithuania (#52.34%).
Discussion
This study updates a previous description of the consumption of
tetracyclines, sulphonamides and trimethoprim, and other anti-
bacterials in the community in EU/EEA countries.2 Most substances
reported in this article are prescribed to treat a wide range of infec-
tions and acne as well as infections with atypical pathogens such
as Chlamydophila pneumoniae, Mycoplasma pneumoniae or
Legionella pneumophila.8 While tetracycline consumption did not
change significantly over time, its seasonal variation significantly
decreased. Four substances represented 99% of consumption of
tetracyclines in the community.
In 2017, the proportional consumption of tetracyclines out of
all antibacterials for systemic use ranged from 2.51% in Italy to
28.22% in the United Kingdom.3 In European countries that are
not part of the ESAC-Net but covered by the WHO Europe
Antimicrobial Medicines Consumption (AMC) Network, there was
also considerable variation, i.e. from <0.1% in North Macedonia to
15.3% in Azerbaijan.9
While the consumption of doxycycline (usually prescribed for
respiratory infections), minocycline and tetracycline (usually pre-
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the consumption of lymecycline (usually prescribed to treat acne
and respiratory infections) increased since 2009, mainly in some
northern EU/EEA countries such as Finland, Norway, Sweden and
the United Kingdom.
Consumption of sulphonamides and trimethoprim [usually pre-
scribed to treat urinary tract infections (UTIs)] and the composition
of this consumption varied considerably between countries. On
average, within the EU/EAA, consumption of sulphonamides and
trimethoprim significantly decreased over time until 2006 and
remained stable thereafter, but seasonal variation continued to
significantly decrease over time. Interestingly, considering the
change in the composition of consumption of sulphonamides and
trimethoprim, the proportion of trimethoprim and derivatives
(J01EA) significantly increased over time compared with that of
the most commonly prescribed subgroup combinations of sul-
phonamides and trimethoprim, including derivatives (J01EE),
as well as other less-consumed sulphonamide subgroups.
Given that total consumption of sulphonamides and trime-
thoprim did not change significantly after 2006, this implies
that consumption of one subgroup was merely replaced by con-
sumption of another subgroup, rather than consumption being
reduced overall.
In the EU/EEA, the average consumption as well as the season-
al variation of the consumption of other antibacterials (J01X) did
not change significantly over time. Nevertheless, there were large
variations between countries with other antibacterials represent-
ing from 0.17% in Ireland to 27.46% in Norway of the consumption
of antibacterials for systemic use in the community in 2017.3 This
might be explained by a preference for treating some UTIs with
methenamine, which does not drive antimicrobial resistance.10 In
European countries that are not part of the ESAC-Net but covered
by the WHO Europe Antimicrobial Medicines Consumption (AMC)
Network considerable variation was also observed, from 1.4% in
Albania to 10.8% in Georgia.9
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Figure 9. Estimated trend (solid line) of consumption of other antibacterials (ATC J01X) in the community based on quarterly data from 25 EU/EEA
countries, 1997–2017. b0, predicted consumption in the first quarter of 1997; b1, predicted increase (if positive)/decrease (if negative) in consumption
per quarter; b2, predicted difference in slope after versus before the first change-point; b3, predicted difference in slope after versus before the second
change-point; b4, predicted difference in slope after versus before the third change-point; b0
S, predicted amplitude of the upward winter and down-
ward summer peak in consumption; b1
S, predicted increase (if positive)/decrease (if negative) of the amplitude of the upward winter and downward
summer peak in consumption per quarter; d, shift in timing of the upward winter and downward summer peak from one year to another. An asterisk
indicates that the result was statistically significant at significance level 0.05.
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In addition, there were large variations between countries and
over time for specific subgroups. Consumption of parenteral glyco-
peptide antibacterials (vancomycin and teicoplanin); polymyxins
(colistin) and imidazole derivatives for systemic use (metronida-
zole and tinidazole) was low in the community in most EU/EEA
countries. Consumption of fusidic acid for systemic use, available
in parenteral and oral formulation, was also low. Countries where
these parenteral substances are prescribed in the community tend
to report a high consumption of other antibacterials expressed in
packages per 1000 inhabitants per day because each package
might represent only one DDD of parenteral antibiotic. As such,
Greece ranked high for its consumption of other antibacterials
expressed in packages per 1000 inhabitants per day because of
its high consumption of parenteral metronidazole, colistin,
vancomycin and teicoplanin, which could be related to outpatient
parenteral antibiotic therapy (OPAT) to treat pneumonia, UTIs and
gastro-intestinal tract infections in Greece.11 Italy is also known for
its consumption of parenteral antibiotics in the community, often
administered at hospital infusion centres.12 Teicoplanin and cef-
triaxone were the most commonly administered parenteral antibi-
otics at these centres.13 Esposito et al.14 predicted that the
demand for OPAT is likely to further increase in Italy due to the po-
tential saving in hospital care costs and improvements in the allo-
cation of limited healthcare resources, with an increased
consumption of teicoplanin until 2010.15 We confirmed that in-
deed teicoplanin for OPAT increased up to 0.06 DDD per 1000
inhabitants per day in Italy until 2010, but decreased steadily
thereafter to 0.03 DDD per 1000 inhabitants per day in 2017.
For France and Italy, the higher ranking for their consumption
of other antibacterials expressed in packages per 1000 inhabitants
per day was also related to the consumption of fosfomycin, which
is dispensed as one dose per package and is commonly prescribed
for the treatment of UTIs in these countries. Some guidelines may
recommend oral fosfomycin as first-line therapy for the treatment
of uncomplicated cystitis.16 In many countries, resistance to
fosfomycin remains low in uropathogenic Escherichia coli, while
increasing resistance to trimethoprim/sulfamethoxazole, which
is still widely used as the first-line agent for the treatment of un-
complicated UTIs, has been reported.17–20 Belgium scored high for
its consumption of other antibacterials expressed in DDD per 1000
inhabitants per day and higher when expressed in packages per
1000 inhabitants per day, which is related to the high consumption
of nitrofuran derivatives (mainly nitrofurantoin) prescribed to treat
uncomplicated cystitis as well as for the long-term prophylaxis of
UTIs.21,22 The absence of consumption of nitrofuran derivatives
reported for Bulgaria, Hungary and Slovakia (2016 data) might
be explained by the fact that nitrofurantoin had to be imported
(due to manufacturing problems) and therefore was not included
in the sales data reported by these countries.
Finally, six substances for parenteral use, i.e. tigecycline
(J01AA12), colistin (J01XB01), fosfomycin (J01XX01), linezolid
(J01XX08), daptomycin (J01XX09) and tedizolid (J01XX11), for
which consumption was reported in 2017, are listed as Reserve
antibiotics in the 2019 WHO Access, Watch or Reserve (AWaRe)
classification list. Six countries, among which two provided total
care data, i.e. community and hospital sector combined, reported
consumption of tigecycline. There also were large variations in the
consumption of colistin among the 22 countries reporting con-
sumption of this antibiotic in the community in 2017. The AWaRe
classification can be used in supporting antibiotic monitoring
and optimal prescribing. Individual countries should follow up
consumption of Reserve antibiotics, which are considered as ‘last
resort’ options for the treatment of confirmed or suspected
infections due to multidrug-resistant organisms. These should be
prioritized as key targets in national stewardship programmes.23
For a more detailed discussion on the limitations of the col-
lected data, we refer to the article on antibacterials for systemic
use, included in this series.4 For a discussion on the limitations
of the statistical approach used in this study and potential
explanations for the common change-points detected through
these analyses, we refer to the tutorial included in this series.6
In conclusion, as for all other main antibiotic groups, there
were large variations between EU/EEA countries in the consump-
tion and composition of the consumption for the tetracyclines,
sulphonamides and trimethoprim, and other antibacterials in the
community. This represents an opportunity to improve the quality
of prescription of these antibiotics in many countries.
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